Clinical Core

临床核心

• 批准号: 9086182
• 负责人: CHRISTOPHER H VAN DYCK
• 金额: $ 39.72万
• 依托单位: YALE UNIVERSITY
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/9086182
• 关键词: Age; Alzheimer' s Disease; Alzheimer' s disease risk; Autopsy; Biological; Biological Markers; Categories; Cellular biology; Cessation of life; Clinical; Clinical Research; Collaborations; Collection; Consent; DNA Library; Data; Data Set; Dementia; Diagnostic; Diagnostics Research; Disease; Enrollment; Evaluation; Exclusion Criteria; First Degree Relative; Future; Genetic Risk; Goals; Measures; Methods; Pathogenesis; Pathology; Peripheral Blood Mononuclear Cell; Pilot Projects; Plasma; Population; Proteomics; Protocols documentation; Research; Research Personnel; Research Project Grants; Research Support; Resources; Specimen; Staging; System; Testing; Therapeutic; Time; Work; disease diagnosis; disease phenotype; inclusion criteria; induced pluripotent stem cell; interest; middle age; mild cognitive impairment; outreach; pre-clinical; programs; repository; study population; therapeutic development; translational neuroscience; validation studies

SUMMARY FOR CLINICAL CORE The over-arching goal of the Clinical Core will be to provide research diagnostic evaluations for a large clinical population with a special emphasis on subjects who are followed longitudinally to provide well- characterized subjects for the research projects conducted by ADRC investigators and collaborators. Important focuses of the Clinical Core as for the Yale ADRC broadly include cell biology, the integration of translational neuroscience, and an emphasis on systematic storage of biospecimens for current and future biomarker studies. While the importance of biomarkers for Alzheimer's disease (AD) diagnosis and therapeutic development is well appreciated, recent advances in targeted proteomics have not been deployed in this field. The Yale ADRC Biomarker/Pathology Core and specific Research Projects will seek to develop these methods with relevance to AD and related disorders. In partnership with these efforts, the Clinical Core will undertake the collection of a wide range of biomarker specimens across the full spectrum of AD cross-sectionally and during the full course of AD longitudinally. Aim 1 will provide for the evaluation and enrollment of approximately 500 subjects who will enter the Core Population for participation in research in five diagnostic categories on the full continuum of AD (from preclinical to dementia), as well as non-AD dementias and normal controls. A diagnostic category of special interest for the Yale ADRC is cognitively normal middle-aged (50-65) first-degree relatives at varying APOE4 genetic risk for AD. Aim 2 will enroll these 500 subjects in the Uniform Data Set (UDS) population and make the UDS measures available to the National Alzheimer's Coordinating Center (NACC) for national studies. Aim 3 will enroll subjects into the Autopsy Program. Aim 4 will provide appropriate subjects for the clinical studies affiliated with the ADRC. Aim 5 will collect and distribute biological specimens to ADRC and other researchers for biomarker studies. These Aims will provide ADRC affiliated investigators the ready ability to test biomarkers once validated in AD dementia in the earliest stages of AD pathogenesis.

临床核心的摘要 临床核心的总体目标是为大型研究提供研究诊断评估 临床人群特别强调了受试者，这些受试者纵向提供了良好的人 为ADRC研究人员和合作者进行的研究项目的主题表征了主题。重要的 临床核心的重点与耶鲁ADRC广泛包括细胞生物学，整合 转化神经科学，并强调当前和未来的生物测量系统存储 生物标志物研究。而生物标志物对阿尔茨海默氏病（AD）诊断和治疗的重要性 开发非常感谢，该领域尚未部署目标蛋白质组学的最新进展。 耶鲁ADRC生物标志物/病理核心和特定研究项目将寻求开发这些方法 与广告和相关疾病有关。与这些努力合作，临床核心将进行 在广告横截面和 在整个AD过程中，纵向。 AIM 1将提供大约评估和注册 500名将进入核心人群的受试者参加五个诊断类别的研究 AD的完整连续体（从临床前到痴呆症）以及非AD痴呆症和正常对照。一个 耶鲁ADRC特殊兴趣的诊断类别是认知正常中年（50-65）一级 APOE4遗传风险的不同亲属。 AIM 2将在统一数据集中招募这500名受试者 （UDS）人口并将UDS措施提供给国家阿尔茨海默氏症协调中心 （NACC）用于国家研究。 AIM 3将注册受试者参加尸检计划。 AIM 4将提供适当的 与ADRC相关的临床研究的受试者。 AIM 5将收集和分发生物标本 致ADRC和其他研究人员进行生物标志物研究。这些目标将为ADRC附属研究人员提供 在AD最早的AD痴呆症中测试生物标志物的现成能力 发病。